STOCK TITAN

Codexis Inc. - CDXS STOCK NEWS

Welcome to our dedicated news page for Codexis (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Codexis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Codexis's position in the market.

Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA, and proteins for the biotech industry. Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase, providing a path to a GMP-grade version. Codexis will receive payments for technical milestones, commercial milestones, and sales-based royalties. The collaboration aims to increase commercial penetration and enable efficient manufacture of mRNA-based therapeutics, potentially impacting millions of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.15%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) achieves gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, enabling the modeling of manufacturing processes for RNAi therapeutics. Pre-commercial customer testing set for 2024 with a full commercial launch anticipated in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.15%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) hosted a virtual KOL event to discuss the growth of RNA interference therapeutics, featuring industry experts and company management. The event highlighted the potential of the Company’s Enzyme-Catalyzed Oligonucleotide Synthesis platform to enable commercial-scale production of RNAi therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) to host virtual KOL event on Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and RNA interference therapeutics manufacturing landscape with industry experts. Event to feature John Maraganore, PhD, and David Butler, PhD, discussing commercial-scale production potential. Management to provide overview of ECO Synthesis™ platform and commercial opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
conferences
-
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) to attend 35th Annual Piper Sandler Healthcare Conference, participating in a fireside chat on November 28, 2023, at 9:30 am ET. The live webcast will be available on the Company’s Investor Relations website, with a 90-day replay archive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
conferences
-
Rhea-AI Summary
Codexis, Inc. announced its financial results for Q3 2023, reporting a decrease in total revenues by 57% compared to the same period last year. The company remains on track to demonstrate gram-scale synthesis with its ECO Synthesis™ platform for RNAi therapeutics production by the end of the year. Codexis also highlighted its strong financial position, projecting positive cash flow by the end of 2026. The company plans to host a virtual ECO Synthesis™ platform-focused KOL event on December 8, 2023, featuring John Maraganore.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
Rhea-AI Summary
Codexis, Inc. (NASDAQ: CDXS) will participate in four upcoming investor conferences. The conferences include Jefferies London Healthcare Conference, Stifel 2023 Healthcare Conference, Stephens Annual Investment Conference, and Craig-Hallum Alpha Select Conference. Management will participate in fireside chats and host investor meetings. Live webcasts and replays will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Codexis, Inc. announces presentation on enzymatic approach to support RNA-based therapeutics manufacturing at TIDES Europe annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
conferences
-
Rhea-AI Summary
Codexis, Inc. to report Q3 2023 financial results and host conference call on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences earnings
Rhea-AI Summary
Codexis CEO Stephen Dilly wins 2023 Bloom Burton Award for leadership at Sierra Oncology and $1.9 billion acquisition by GSK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.18%
Tags
none
Codexis Inc.

Nasdaq:CDXS

CDXS Rankings

CDXS Stock Data

201.77M
63.61M
3.22%
82.74%
3.39%
Paint and Coating Manufacturing
Manufacturing
Link
US
Portland

About CDXS

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop